Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab Induction Dosing in Acute Severe Ulcerative Colitis (PREDICT UC)
NCT02770040Phase 4Completed
- Sponsor
- Austin Health
- Start
- Jul 2016
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of infliximab in ulcerative colitis (UC), sponsored by Austin Health. Started Jul 2016; status: completed.
02
Drugs
infliximab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02770040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02770040.